Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial

Triple-negative breast cancer (TNBC) is a highly heterogeneous disease, and molecular subtyping may result in improved diagnostic precision and targeted therapies. Our previous study classified TNBCs into four subtypes with putative therapeutic targets. Here, we conducted the FUTURE trial (ClinicalT...

詳細記述

保存先:
書誌詳細
出版年:Cell Res
主要な著者: Jiang, Yi-Zhou, Liu, Yin, Xiao, Yi, Hu, Xin, Jiang, Lin, Zuo, Wen-Jia, Ma, Ding, Ding, Jiahan, Zhu, Xiaoyu, Zou, Jianjun, Verschraegen, Claire, Stover, Daniel G., Kaklamani, Virginia, Wang, Zhong-Hua, Shao, Zhi-Ming
フォーマット: Artigo
言語:Inglês
出版事項: Springer Singapore 2020
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8027015/
https://ncbi.nlm.nih.gov/pubmed/32719455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41422-020-0375-9
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料